Podcasts about diversion control

Are benzos effective for treating anxiety? Insomnia? Seizures? If they aren't safe, what is the evidence? How many BIND symptoms are there? Could these be permanent? And what about COVID? Tune in for the surprising answers.In today's episode, we ask some key questions about benzos and provide real answers, with evidence to back them. We also share questions from our international listeners on CBD and probiotics, and we hear a powerful story of one woman's struggle with her third attempt at withdrawal. This one if chock full of information, and I hope you'll join us.https://www.easinganxiety.com/post/the-facts-what-do-we-really-know-about-benzos-and-bind-bfp107Video ID: BFP107Chapters 0:00:00 INTRODUCTION0:01:16 About the Last Episode0:02:17 Behind the Scenes Work0:03:18 Hurricane Ian0:05:38 MAILBAG0:05:54 Benzo Belly and Probiotics (Jon)0:11:48 CBD and Withdrawal (Julie)0:17:29 BENZO STORY (Jessica)0:26:48 Response from D0:31:20 FEATURE: Benzo Facts0:32:48 Are Benzos Effective?0:35:23 Are Benzos Safe?0:43:49 Can You Be Addicted to Benzos?0:44:46 Is BIND an Official Term?0:47:21 How Many BIND Symptoms Are There?0:52:05 Is BIND Permanent?0:56:42 Are Z-drugs the Same as Benzos?0:57:22 Do Benzos Have an Effect on COVID?1:00:58 MOMENT OF PEACE Episode Resources The following resource links are provided as a courtesy to our listeners. They do not constitute an endorsement by Easing Anxiety of the resource or any recommendations or advice provided therein.SITE RESOURCES— Benzodiazepine Action Work Group (BAWG) — https://benzoaction.org— Benzodiazepine Information Coalition (BIC) — https://benzoinfo.com— The Alliance for Benzodiazepine Best Practices — https://benzoreform.org— Blazing Benzos Facebook Group — https://m.facebook.com/groups/1205287192817668/MAILBAGGrinspoon, Peter. Cannabidiol (CBD): What we know and what we don't. Harvard Health Publishing. September 24, 2021. Accessed September 27, 2022. https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476. FEATUREAshton, C. Heather. Benzodiazepines: How They Work and How to Withdraw (aka The Ashton Manual). 2002. Accessed April 13, 2016. http://www.benzo.org.uk/manual. Ashton, C. Heather. Benzodiazepines: The Still Unfinished Story. (Speech at Beat the Benzos Launch Conference, Croyden, London, England). https://www.benzo.org.uk/ashspeech.htm. Bachhuber, Marcus A., Sean Hennessy, Chinazo O. Cunningham and Joanna L. Starrels. “Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996-2013.” American Journal of Public Health (AJPH) (April 2016). Accessed April 7, 2018. doi:10.2105/AJPH.2016.303061. Benzodiazepine Information Coalition (BIC). Withdrawal & Post Withdrawal Symptoms. Accessed September 29, 2022. https://www.benzoinfo.com/benzodiazepine-withdrawal-post-withdrawal-symptoms/. Breilmann J, Girlanda F, Guaiana G, Barbui C, Cipriani A, Castellazzi M, Bighelli I, Davies SJC, Furukawa TA, Koesters M. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews 2019, Issue 3. Art. No.: CD010677. DOI: 10.1002/14651858.CD010677.pub2. Accessed 27 September 2022. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010677.pub2/full. Commonwealth of Pennsylvania. Prescribing Guidelines for Pennsylvania: Safe Prescribing Benzodiazepines for Acute Treatment of Anxiety & Insomnia. Updated May 15, 2017. Accessed April 7, 2018. http://www.health.pa.gov/My%20Health/Diseases%20and%20Conditions/M-P/opioids/Documents/PA%20Guidelines%20on%20Benzo%20Prescribing.pdf. Easing Anxiety. BIND Symptoms. https://easinganxiety.com/symptoms. Foster, D E. Benzo Free: The World of Anti-Anxiety Drugs and the Reality of Withdrawal. Erie, CO: Denim Mountain Press, 2018. https://easinganxiety.com/book. Frances, Allen. Yes, Benzos Are Bad for You. Pro Talk: A Rehabs.com Community. June 10, 2016. Accessed October 13, 2016. https://www.rehabs.com/pro-talk-articles/yes-benzos-are-bad-for-you/. Guina J, Merrill B. Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives. J Clin Med. 2018 Jan 30;7(2):17. doi: 10.3390/jcm7020017. PMID: 29385731; PMCID: PMC5852433. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852433/. Kripke, D. F., R.D. Langer and L.E. Kline. Hypnotics' Association with Mortality or Cancer: A Matched Cohort Study. BMJ Open 2(e000850)(2012). Accessed June 21, 2017. doi:10.1136/bmjopen-2012-000850. Lakhani, Nina, Drugs Linked to Brain Damage 30 Years Ago, Independent, November 7, 2010, accessed March 4, 2017, https://www.independent.co.uk/life-style/health-and-families/health-news/drugs-linked-to-brain-damage-30-years-ago-2127504.html. New York City Department of Health and Mental Hygiene (NYC DOHMH). City Health Information: Judicious Prescribing of Benzodiazepines. 35(2)(2016). https://docs.wixstatic.com/ugd/990dad_167113513c9445f8bc77a77370ce649f.pdf. Park, H.Y., Kwon, J., An, S.K. et al. A nationwide cohort study of the association of benzodiazepines with SARS-CoV-2 infection and clinical outcomes. Sci Rep 12, 15947 (2022). https://doi.org/10.1038/s41598-022-20335-z. U.S. Drug Enforcement Agency (DEA). Office of Diversion Control; Drug & Chemical Evaluation Section: Benzodiazepines (January 2013). Accessed March 6, 2017. https://www.deadiversion.usdoj.gov/drug_chem_info/benzo.pdf. U.S. Food & Drug Administration. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. September 23, 2020. Accessed September 27, 2022. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class.  The PodcastThe Benzo Free Podcast provides information, support, and community to those who struggle with the long-term effects of anxiety medications such as benzodiazepines (Xanax, Ativan, Klonopin, Valium) and Z-drugs (Ambien, Lunesta, Sonata). WEBSITE: https://www.easinganxiety.comMAILING LIST: https://www.easinganxiety.com/subscribe YOUTUBE: https://www.youtube.com/@easinganx DISCLAIMERAll content provided by Easing Anxiety is for general informational purposes only and should never be considered medical advice. Any health-related information provided is not a substitute for medical advice and should not be used to diagnose or treat health problems, or to prescribe any medical devices or other remedies. Never disregard medical advice or delay in seeking it. Please visit our website for our complete disclaimer at https://www.easinganxiety.com/disclaimer. CREDITSMusic provided / licensed by Storyblocks Audio — https://www.storyblocks.com Benzo Free Theme — Title: “Walk in the Park” — Artist: Neil Cross PRODUCTIONEasing Anxiety is produced by… Denim Mountain Presshttps://www.denimmountainpress.com ©2022 Denim Mountain Press – All Rights Reserved

In our last episode of this series, we learned how passage of the Ensuring Patient Access and Effective Drug Enforcement Act took away the DEA’s most effective diversion control enforcement tool, the immediate suspension order. The bill was shaped in large part by a former DEA lawyer. On this episode, you’ll hear more stories about Congressman and high ranking government agency officials who have played key roles in deciding the fate of drug bills and policies; and weeks later went to work in the pharmaceutical industry. 24 years ago, the medical director for the FDA played a key role in approving OxyContin without clinical trials and shortly thereafter, left to go to work for Purdue Pharma. In this podcast you’ll hear a clip from “The Sentence that Helped Set Off the Opioid Crisis” a podcast by Caitlin Esch and Krissy Clark in their “Uncertain Marketplace” series that frames a key reason why OxyContin was approved by the FDA and the people involved in that decision. Back in 2007, a member of Congress led an all-night effort to pass legislation that prohibits the government from negotiating lower Medicare drug prices. Today we’ll play a “60 Minutes” piece by Steve Kroft from 2007, that reveals what happened after the bill was passed and why, in our country an EpiPen costs $608 and in Britain, where they can negotiate drug prices with the manufacturers, it costs just $70. The Congressman who led passage of that bill became a leading lobbyist for the Pharmaceutical Industry after its passage. Today in the final part of our 4-part series with Mr. Joe Rannazzisi, he shares his reaction when his department was asked to be more like the FDA. As we pick up our discussion, Mr. Rannazzisi talks about the shakeup in leadership that led to his departure from the DEA. Join us on this podcast, the final episode in our 4 part series, for more candid conversation with the former head of the Department of Diversion Control for the DEA, Mr. Joseph Rannazzisi.

When a key member of the government’s legal team went to work for the pharmaceutical industry, the job of diversion control enforcement changed dramatically. In this episode, Mr. Joseph Rannazzisi, who for over a decade, was the front man in the government’s battle against the opioid epidemic, shares a first-hand account of what happened when Congress took the word of an industry attorney over an agency that was actually enforcing the law. Today, in the third part of our 4-part series, you’ll hear more of Mr. Rannazzisi’s unfiltered comments on the passage of the Ensuring Patient Access and Effective Enforcement Act and the Congressional leaders behind it. “This doesn’t ensure patient access and it doesn’t help drug enforcement at all. What this bill does has nothing to do with the medical process. What this bill does is take away DEA’s ability to go after a pharmacist, a wholesaler, manufacturer or distributor,” he said. “This was a gift. A gift to the industry.” Greg is joined on this episode by guest, award-winning author of “American Overdose”, Chris McGreal. McGreal’s book is a comprehensive portrait of the greed, corruption and indifference that led our country into the worst health crisis in American history. Additionally, Mr. McGreal is an investigative journalist for the Guardian, who in 2016, wrote a compelling story about Mr. Rannazzisi titled “Opioid epidemic: ex-DEA official says Congress is protecting drug makers.” https://www.theguardian.com/us-news/2016/oct/31/opioid-epidemic-dea-official-congress-big-pharma Listen to this podcast, the third in our 4 part series, for more candid conversation with the former head of the Department of Diversion Control for the DEA, Mr. Joseph Rannazzisi.

This is the 2nd in our 4 part series with the former head of the Office of Diversion Control for the DEA, Mr. Joseph Rannazzisi. We began this series by talking about the surprisingly candid report released on December 19th, 2018 by the Energy and Commerce Committee titled “Red Flags and Warning Signs Ignored: Opioid Distribution and Enforcement Concerns in West Virginia”. The purpose of the report was to investigate allegations of “opioid dumping” in West Virginia. In today’s podcast with Mr. Rannazzisi, who for over a decade was the front man in the government’s battle against the opioid epidemic, you’ll hear an in-depth conversation about how the diversion controls, that were supposed to be in place to protect the public from “opioid dumping”, failed in epic proportions. He gives a candid account of the friction and distrust that emerged between DEA and the DOJ that resulted in a breakdown in their ability to protect the American public from shipments of mass quantities of opioids, previously flagged as suspect. He’ll share his unfiltered comments on the passage of the Ensuring Patient Access and Effective Enforcement Act, a game-changing piece of legislation and you’ll learn about the people who were responsible for the legislative win for the pharmaceutical industry. Mr. Rannazzisi offers his insights into the inter-workings of the Office of Diversion Control. As the department’s former leader, he was responsible for cracking down on doctors, pharmacies, drug manufacturers and distributors who did not follow the nation’s prescription drug laws. You may recall him from the 60 Minutes story titled “The Whistleblower” last fall. Greg is joined on this episode by guest, award winning investigative reporter, Pat Beall from the Palm Beach Post. Pat won Journalist of the Year for her work on The Post’s coverage of the heroin crisis, including profiles of the 216 people who died in 2015 from heroin-related overdoses, calculation of the cost of hospital care related to heroin treatment and a story linking Florida Attorney General Pam Bondi to a fraudulent drug-screening company. Listen to this podcast, the second in our 4 part series, for a behind the scenes look at who was behind law changes that helped fuel America’s opioid epidemic.

On December 19th, 2018, the Energy and Commerce Committee released a long awaited report titled “Red Flags and Warning Signs Ignored: Opioid Distribution and Enforcement Concerns in West Virginia”. The purpose of the report was to investigate allegations of “opioid dumping” in West Virginia. Today, we begin a 4-part series with Joseph Rannazzisi, who for over a decade, was the front man in the government’s battle against the opioid epidemic. Mr. Rannazzisi provides in-depth commentary on the Energy and Commerce Committee’s eye opening report, which, notably, is no longer available on the department’s website. Prior to the passage of the Ensuring Patient Access and Effective Drug Enforcement Act in 2016, Mr. Rannazzisi warned congress that passage of the bill would cripple their ability to regulate rogue distributors who were dumping millions of opioids across the country. Today, you’ll hear Mr. Rannazzisi’s unfiltered comments on this game-changing piece of legislation. As head of the Office of Diversion Control for the Drug Enforcement Administration, he was responsible for cracking down on doctors, pharmacies, drug manufacturers and distributors who did not follow the nation’s prescription drug laws. You may recall him from the 60 Minutes story titled “The Whistleblower” last fall. Greg is joined on this episode by guest, Pulitzer Prize winning journalist, Eric Eyre. Mr. Eyre received the distinguished award for courageous reporting, performed in the face of powerful opposition, to expose the flood of opioids flowing into depressed West Virginia counties with the highest overdose death rates in the country. For more on Mr. Eyre’s award winning work go to: https://www.pulitzer.org/winners/eric-eyre Listen to this podcast to learn more about who was behind law changes that helped fuel America’s opioid epidemic.

Dr. Erin Albert welcomes back Joseph T. Rannazzisi Deputy Assistant Administrator (RETIRED), Office of Diversion Control, U.S. Drug Enforcement Administration (DEA) for the final segment of the 3 part series.  About Joseph T. Rannazzisi Joe Rannazzisi, JD, RPh, began his career with the U.S. Drug Enforcement (DEA) in 1986. He served as a staff pharmacist at the Veterans Administration for the 18 months preceding his employment with DEA. During his DEA career, he served as a Diversion Investigator (Indianapolis), Special Agent/Criminal Investigator (Indianapolis/Detroit), Clandestine Laboratory Coordinator (Detroit), Homicide Task Force Supervisor (Detroit), Staff Coordinator (Domestic Operations-Headquarters), Section Chief (Dangerous Drugs and Chemicals Section-Headquarters), Assistant Special Agent in Charge (Detroit), and Deputy Chief (Office of Enforcement Operations-Headquarters). In January 2006 he was appointed to Deputy Assistant Administrator in the Office of Diversion Control, a position he held until his retirement in October 2015. In this capacity, Mr. Rannazzisi was responsible for overseeing and coordinating major pharmaceutical and chemical diversion investigations; the drafting and promulgating of regulations; establishing drug production quotas; and conducting liaison with the pharmaceutical industry, international governments, state governments, other federal agencies, and local law enforcement agencies. He earned a BS degree in pharmacy from Butler University and a JD degree from the Detroit College of Law at Michigan State University. He is a Registered Pharmacist in the State of Indiana and a member of the Michigan State Bar Association. See omnystudio.com/listener for privacy information.

Dr. Erin Albert welcomes back Joseph T. Rannazzisi Deputy Assistant Administrator (RETIRED), Office of Diversion Control, U.S. Drug Enforcement Administration (DEA) for the final segment of the 3 part series.  About Joseph T. Rannazzisi Joe Rannazzisi, JD, RPh, began his career with the U.S. Drug Enforcement (DEA) in 1986. He served as a staff pharmacist at the Veterans Administration for the 18 months preceding his employment with DEA. During his DEA career, he served as a Diversion Investigator (Indianapolis), Special Agent/Criminal Investigator (Indianapolis/Detroit), Clandestine Laboratory Coordinator (Detroit), Homicide Task Force Supervisor (Detroit), Staff Coordinator (Domestic Operations-Headquarters), Section Chief (Dangerous Drugs and Chemicals Section-Headquarters), Assistant Special Agent in Charge (Detroit), and Deputy Chief (Office of Enforcement Operations-Headquarters). In January 2006 he was appointed

Part 2 - We address:   -Rescheduling of drugs, ex: benzodiazepines -Opioid crisis -Heroin addiction -How we might fix the problem of opioid addiction in the US   Mr. Joseph T. Rannazzisi — Deputy Assistant Administrator (RETIRED), Office of Diversion Control, U.S. Drug Enforcement Administration Joe Rannazzisi, JD, RPh, began his career with the U.S. Drug Enforcement(DEA) in 1986. He served as a staff pharmacist at the Veterans Administration for the 18 months preceding his employment with DEA. During his DEA career, he served as a Diversion Investigator (Indianapolis), Special Agent/Criminal Investigator (Indianapolis/Detroit), Clandestine Laboratory Coordinator (Detroit), Homicide Task Force Supervisor (Detroit), Staff Coordinator (Domestic Operations-Headquarters), Section Chief (Dangerous Drugs and Chemicals Section-Headquarters), Assistant Special A

Part 2 - We address:   -Rescheduling of drugs, ex: benzodiazepines -Opioid crisis -Heroin addiction -How we might fix the problem of opioid addiction in the US   Mr. Joseph T. Rannazzisi — Deputy Assistant Administrator (RETIRED), Office of Diversion Control, U.S. Drug Enforcement Administration Joe Rannazzisi, JD, RPh, began his career with the U.S. Drug Enforcement(DEA) in 1986. He served as a staff pharmacist at the Veterans Administration for the 18 months preceding his employment with DEA. During his DEA career, he served as a Diversion Investigator (Indianapolis), Special Agent/Criminal Investigator (Indianapolis/Detroit), Clandestine Laboratory Coordinator (Detroit), Homicide Task Force Supervisor (Detroit), Staff Coordinator (Domestic Operations-Headquarters), Section Chief (Dangerous Drugs and Chemicals Section-Headquarters), Assistant Special Agent in Charge (Detroit), and Deputy Chief (Office of Enforcement Operations-Headquarters). See omnystudio.com/listener for privacy information.

Joseph T. Rannazzisi Deputy Assistant Administrator (RETIRED), Office of Diversion Control, U.S. Drug Enforcement Administration Joe Rannazzisi, JD, RPh, began his career with the U.S. Drug Enforcement(DEA) in 1986. He served as a staff pharmacist at the Veterans Administration for the 18 months preceding his employment with DEA. During his DEA career, he served as a Diversion Investigator (Indianapolis), Special Agent/Criminal Investigator (Indianapolis/Detroit), Clandestine Laboratory Coordinator (Detroit), Homicide Task Force Supervisor (Detroit), Staff Coordinator (Domestic Operations-Headquarters), Section Chief (Dangerous Drugs and Chemicals Section-Headquarters), Assistant Special Agent in Charge (Detroit), and Deputy Chief (Office of Enforcement Operations-Headquarters). In January 2006, he was appointed to Deputy Assistant Administrator in the Office of Diversion Control, a p

Joseph T. Rannazzisi Deputy Assistant Administrator (RETIRED), Office of Diversion Control, U.S. Drug Enforcement Administration Joe Rannazzisi, JD, RPh, began his career with the U.S. Drug Enforcement(DEA) in 1986. He served as a staff pharmacist at the Veterans Administration for the 18 months preceding his employment with DEA. During his DEA career, he served as a Diversion Investigator (Indianapolis), Special Agent/Criminal Investigator (Indianapolis/Detroit), Clandestine Laboratory Coordinator (Detroit), Homicide Task Force Supervisor (Detroit), Staff Coordinator (Domestic Operations-Headquarters), Section Chief (Dangerous Drugs and Chemicals Section-Headquarters), Assistant Special Agent in Charge (Detroit), and Deputy Chief (Office of Enforcement Operations-Headquarters). In January 2006, he was appointed to Deputy Assistant Administrator in the Office of Diversion Control, a position he held until his retirement in October 2015. In this capacity, Mr. Rannazzisi was responsible for overseeing and coordinating major pharmaceutical and chemical diversion investigations; the drafting and promulgating of regulations; establishing drug production quotas; and conducting liaison with the pharmaceutical industry, international governments, state governments, other federal agencies, and local law enforcement agencies. Mr. Rannazzisi earned a BS degree in pharmacy from Butler University and a JD degree from the Detroit College of Law at Michigan State University. He is a Registered Pharmacist in the State of Indiana and a member of the Michigan State Bar Association. Mr. Rannazzisi's LinkedIn Profile: https://www.linkedin.com/in/joseph-rannazzisi-35a35a58/ Careers at DEA: https://www.dea.gov/careers/agent/mobile/diversity.html See omnystudio.com/listener for privacy information.